Madison Vaccines Incorporated (Madison)

Oncology Corporate Profile

HQ Location

505 South Rosa Road, Suite 201
Madison, WI 53719

Company Description

MVI is developing DNA vaccines intended to treat prostate cancer at crucial stages in the disease. MVI's lead vaccine is being developed to prevent or delay both the onset of bone metastases and the early use of physical or hormonal castration (androgen deprivation therapy) for men with biochemically recurrent prostate cancer (rising PSA after prostate surgery or radiation). MVI's second vaccine is being developed for men with early metastatic disease, to help prolong the duration of disease control they gain from current androgen deprivation therapies.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MVI-816plasmid DNA vaccineProstate cancerII
MVI-118plasmid DNA vaccineProstate cancerPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display